

# **Recent Trends in Management of Gastrointestinal Stromal Tumors**

*Essay*

Submitted for the Partial Fulfillment of  
Master Degree in **General Surgery**

*By*

**Ahmed Atef Mohamed Hosny**

M.B., B.Ch

Faculty of Medicine - Ain Shams University

*Under Supervision of*

**Prof. Dr. Ibrahim Mohamed  
Hassanein El-Ghazawy**

Professor of General Surgery

Faculty of Medicine-Ain Shams University

**Dr. Mohamed Fayek Mahfouz**

Lecturer of General Surgery

Faculty of Medicine-Ain Shams University


**Dr. Moheb Shoraby Eskandaros**

Lecturer of General Surgery

Faculty of Medicine-Ain Shams University

**Faculty of Medicine  
Ain Shams University**

**2014**



# Acknowledgement

*First of all, thanks to Allah whose magnificent help was the main factor in completing this work,*

*I would like to express my deepest appreciation, respect and thanks to Prof. Dr. Ibrahim Mohamed Hassanein El-Ghazawy, Professor of General Surgery, Faculty of Medicine - Ain Shams University, for his continuous guide in all aspects of life beside his great science, knowledge and information.*

*It has been a great honor for me to work under his generous supervision Great words really needed to express my gratitude, sincere appreciation and respect to Dr. Mohamed Fayed Mahfouz, Lecturer of General Surgery, Faculty of Medicine, Ain Shams University, who continued to provide me his guidance ever since. Without his great help, teaching and supervision, this work would not have been completed.*

*No words can express my deep sincere feelings Towards Dr. Moheb Shoraby Eskandaros, Lecturer of General Surgery, Faculty of Medicine, Ain Shams University for his continuous encouragement, guidance and support he gave me throughout the whole work. It has been a great honor for me to work under his generous supervision.*

## Contents

Subjects	Page
List of abbreviations.....	III
List of Figures .....	IV
List of Tables.....	VI
• <b>Introduction</b> .....	1
• <b>Pathology of Gastrointestinal Stromal Tumors</b> .....	4
♦ Epidemiology of GISTs .....	4
♦ Interstitial Cells of Cajal as the cells of origin.....	6
♦ Gross Pathology .....	6
♦ Histology of GISTs .....	8
♦ Immunohistochemical features of GIST's.....	14
♦ Pathogenesis of GISTs .....	17
♦ Differential Diagnosis of GISTs .....	18
♦ Prognosis, risk assessment and recurrence risk of GISTs.	21
♦ Rare GIST presentations .....	30
• <b>Diagnosis of Gastrointestinal Stromal Tumors</b> ...	35
♦ Clinical picture.....	35
♦ Radiological studies for GISTs .....	38
♦ Endoscopy for GIST .....	45



## *List of Contents*

---

♦ Immunohistochemistry .....	52
♦ Mutational Analysis .....	55
• <b>Treatment of GIST .....</b>	<b>57</b>
♦ Multidisciplinary Approach .....	58
♦ Role and principles of surgery for GIST.....	59
♦ Endoscopic Role in GIST Treatment.....	65
♦ Endoscopic Surveillance.....	67
♦ Imatinib for the Treatment of GIST in Advanced Disease Phase.....	69
♦ Imatinib in Adjuvant Setting.....	76
♦ Imatinib in Neoadjuvant Setting .....	80
♦ Molecular Subtypes and Response to Second-line Therapy for GIST .....	82
♦ Novel TKI agents.....	83
• <b>Response Evaluation and Surveillance .....</b>	<b>86</b>
• <b>Summary.....</b>	<b>95</b>
• <b>References.....</b>	<b>98</b>
• <b>Arabic Summary</b>	

## List of Abbreviations

<b>CML</b>	Chronic myeloid leukemia
<b>CT</b>	Computed tomography
<b>DOG1</b>	Discovered on GIST
<b>EUS</b>	Endoscopic ultrasound
<b>EUS-FNA</b>	Endoscopic ultrasound fine needle aspiration
<b>ESMO</b>	European society for medical oncology
<b>FDG-PET</b>	Fluorodeoxyglucose positron tomography
<b>GIST</b>	Gastrointestinal stromal tumor
<b>HPF</b>	High power field
<b>ICC</b>	Interstitial cell of Cajal
<b>MRI</b>	Magnetic resonance imaging
<b>SUVmax</b>	Maximum standardized uptake value
<b>NCCN</b>	National comprehensive cancer network
<b>OS</b>	Overall survival
<b>PR</b>	Partial response
<b>PDGFR-a</b>	Platelet derived growth factor alpha
<b>PET</b>	Positron emission tomography
<b>PET CT</b>	Positron emission tomography computed tomography
<b>PFS</b>	Progression free survival
<b>PD</b>	Progressive disease
<b>RTK</b>	Receptor tyrosine kinase
<b>RFS</b>	Recurrence free survival
<b>SD</b>	Stable disease
<b>SDH</b>	Succinate dehydrogenase gene
<b>TKI</b>	Tyrosine kinase inhibitor

## List of Figures

<b><u>No.</u></b>	<b><u>Figure</u></b>	<b><u>Page</u></b>
<b><u>1</u></b>	A and B, Large gastrointestinal stromal tumor (GIST) gross pathology. The patient underwent subtotal gastrectomy and splenectomy to remove the large locally invasive GIST.	<b>8</b>
<b><u>2a&amp;b</u></b>	Different histological patterns.	<b>12-13</b>
<b><u>3</u></b>	Immunohistochemical staining for KIT in GIST. A, KIT+ GIST with a KIT exon 11 mutation. B, KIT negative GIST with a PDGFRA mutation.	<b>15</b>
<b><u>4</u></b>	Mutations in GIST.	<b>16</b>
<b><u>5</u></b>	Nomogram.	<b>27</b>
<b><u>6</u></b>	Computed tomographic scan of a gastrointestinal stromal tumor (GIST). Large GIST of the stomach showing heterogenous enhancement and ulceration.	<b>40</b>
<b><u>7</u></b>	Different computed tomographic scans of a gastrointestinal stromal tumor (GIST) arising from the stomach	<b>41</b>
<b><u>8</u></b>	A and B, Endoscopic images of a gastrointestinal stromal tumor depicted. The tumor appears as a smooth bulge into the gastric lumen, with a normal overlying mucosa.	<b>46</b>

<b><u>No.</u></b>	<b><u>Figure</u></b>	<b><u>Page</u></b>
<b><u>2</u></b>	A and B, Endoscopic ultrasound (EUS) of a gastrointestinal stromal tumor.	<b>48</b>
<b><u>10</u></b>	A, Spindle cell-type histologic pattern characteristic of approximately 70% of gastrointestinal stromal tumors (GISTs). B, Immunohistochemical staining showing KIT-positive staining characteristic of approximately 95% of GISTs.	<b>53</b>
<b><u>11</u></b>	Suggested algorithm for management of suspected gastrointestinal stromal tumors (GISTs).	<b>59</b>
<b><u>12</u></b>	Responding hepatic and peritoneal metastases in a patient with advanced gastrointestinal stromal tumor.	<b>76</b>
<b><u>13</u></b>	Responding hepatic metastasis with pseudoprogession in a patient with duodenal gastrointestinal stromal tumor.	<b>90</b>
<b><u>14</u></b>	Recurrence with new intratumoral nodules in a patient with small bowel gastrointestinal stromal tumor.	<b>91</b>

## List of Tables

<b><u>No.</u></b>	<b><u>Table</u></b>	<b><u>Page</u></b>
<b><u>1</u></b>	Differential Diagnosis for GIST.	<b>21</b>
<b><u>2</u></b>	NIH risk stratification of primary GIST according to tumor size and mitotic activity, a consensus approach 2002 (HPF corresponding to 5 mm <sup>2</sup> ).	<b>23</b>
<b><u>3</u></b>	Risk classification of progressive disease adapted from Miettinen and Lasota. Data are based on long- term follow-up of 1,055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal GISTs.	<b>25</b>
<b><u>4</u></b>	Risk classification of progressive disease according to Joensuu.	<b>26</b>
<b><u>5</u></b>	TNM classification of GIST (7th edition of AJCC and UICC).	<b>28</b>
<b><u>6</u></b>	GISTs and their differential diagnosis: immuno-histochemistry and Molecular diagnostics (MD).	<b>54</b>
<b><u>7</u></b>	Treatment in localized and advanced phase of the different molecular subtypes of GIST.	<b>75</b>
<b><u>8</u></b>	Tyrosine kinase inhibitors approved and in development for the treatment of GIST.	<b>85</b>
<b><u>9</u></b>	Modified CT Response Evaluation Criteria.	<b>89</b>



## Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms accounting for 1-2% of all neoplasms of the digestive tract. GISTs were previously considered smooth muscle tumors but are now thought to arise from stem cell precursors of the interstitial cells of Cajal, the neural network that regulates gastrointestinal motility by generating spontaneous electrical slow waves in the gastrointestinal tract (*Vinay and Gregory, 2011*).

The discovery of the c-kit proto-oncogene, a tyrosine kinase receptor in GIST neoplasms has revolutionized the ability to differentiate these lesions as separate entities from other mesenchymal, myogenic and neurogenic subepithelial tumors. Immunohistochemical staining for the tyrosine kinase receptor with c-kit (also referred as CD117) has become a definite feature of GISTs and is present in approximately 95% of these lesions (*Miettinen and Lasota, 2006*).

In most series, gastric tumors are found in 45-65% of the GIST cases followed by tumors of small bowel (15-25%), large bowel including the rectum (5-10%), esophagus (5-10%) and duodenum (3-5%) (*Machairas et al., 2010*).

The manifestations of GISTs vary widely. Seventy percent of the patients are symptomatic, 20% are

asymptomatic and 10% are detected at autopsy. Of those with symptoms, the majority (35%) are presented with gastrointestinal bleeding. Other presenting symptoms are abdominal pain (32%) and the presence of a palpable mass (13%) (**Robson et al., 2004**).

Contrast enhanced computed tomography is the imaging modality of choice for the initial evaluation, staging and monitoring of treatment responses in GIST. Endoscopic ultrasound (EUS) is the most accurate and preferred method of imaging for GISTs. Cytological tissue samples can be obtained through endoscopic ultrasound-fine needle aspiration (EUS-FNA). This technique has the advantage of establishing a diagnosis with reasonable certainty while avoiding the risk of intraperitoneal seedling of the tumor (**Faigel and Abulhawa, 2012**).

GISTs have a highly variable biological behavior. Although only 10-30% of GISTs are clinically malignant, all GISTs harbor some malignant potential. Therefore, primary GISTs are not classified as “benign” or “malignant” but are rather stratified by the probability of recurrence after complete resection. GISTs are stratified into very low, low, moderate and high risk on the basis of their location, size and mitotic rate. Tumor location and size along with mitotic rate (mitosis/50high power field) are reproducible predictors of recurrence risk following complete resection (**Han et al., 2012**).

The most important prerequisite for an optimal medical care of GIST patients is a multidisciplinary approach to the diagnostic and therapeutic planning. Surgical resection remains the only potential curative treatment for GISTs. The reported respectability rate for localized primary GIST is 70-80%. The high rate of recurrence, even after complete resection, fostered the need for evaluating the role of targeted therapy in the context of adjuvant treatment. There is controlled evidence of a benefit for adjuvant imatinib in GIST in terms of both survival and relapse free survival. Sumitinib, a multitargeted kinase inhibitor, is effective against imatinib resistant or intolerant GIST patients. Novel tyrosine kinase inhibitors including nilotinib and masitinib are in their most mature phase of development (*Bareck et al., 2013*).

The screening of patients with a predisposition to the development of GIST and surveillance of completely resected GISTs or during neoadjuvant treatment of unresectable GISTs present unique challenges to the surgical and medical oncologist. Flourodeoxyglucose positron emission tomography (FDG-PET) is highly sensitive and specific in response evaluation of GISTs to systemic treatment (*Choi, 2011*).

# **Pathology of Gastrointestinal Stromal Tumors**

Gastrointestinal stromal tumors (GISTs) initially classified as smooth muscle or neural tumors. In 1983, Mazar and Clark introduced the term 'stromal tumor', which became widely accepted in the early 1990's when Miettinen, et al. were able to show the immunohistochemical expression of CD34 in these tumors that was helpful to separate them from leiomyomas, leiomyosarcomas and schwannomas.

## 1. Epidemiology of GISTs:

Gastrointestinal stromal tumors are rare tumors with an estimated worldwide incidence of approximately 10-20 per million population annually and present 0.1-3 % of all gastrointestinal cancers. It is the most common (80%) mesenchymal tumor of the gastrointestinal tract and represents 5% of all sarcomas. Malignancy possibility is 20-30%. GISTs have a reported incidence of 9 to 14 cases per million per year in most countries in population based studies (*Blay et al., 2012*).

Estimates of the incidence of GISTs in the USA before 2000 are largely unreliable, primarily arising to inconsistencies in the diagnosis of GISTs. The age-adjusted yearly incidence was estimated to be 0.68/100,000 on the basis

of 1458 cases diagnosed between 1992 and 2000. More accurate estimates, which are based on the rates of accrual onto clinical trials, place the incidence range of 3000 to 6000 new diagnosis annually in the USA (*Demetri et al., 2010*).

The yearly incidence of clinically evident GISTs in Europe is approximately 15 cases per one million habitants. However, considering two more recent studies, asymptomatic micro GISTs (0.2-10mm) of the stomach have been reported in up to 35% of Japanese patients, resected of gastric cancer and 22.5% in autopsies of German people above 50 years of age. These minute GISTs often contain an oncogenic mutation in the KIT or PDGFR- $\alpha$  gene comparable to mutations in clinically manifest GIST's (*Bareck et al., 2013*).

At the time of diagnosis, the majority of patients with GIST are approximately 60 years old with no clear gender predilection, however, some studies show some increased prevalence in men than women and black races more than white too. Rarely, GISTs occur in children and young adults and these pediatric GISTs are considered as a separate entity and occur predominantly in the second decade (*Janeway et al., 2007*).

Although most GISTs are sporadic, familial GISTs (patients with germ line KIT mutations) are rare, however, well described in the literature. Furthermore, GISTs can also

be associated with hereditary syndromes as neurofibromatosis type I, Carney's triad (gastric GIST, paraganglionoma and pulmonary chondroma) and Carney Startakis syndrome (paraganglionoma and gastric GIST) (*Hunt et al., 2003*).

## 2- Interstitial Cells of Cajal as the cells of origin:

GISTs are mesenchymal tumors thought to arise from the interstitial cells of Cajal (ICC's), the pacemaker cell of the gastrointestinal tract. In 1990's, the similarities between GISTs cells and the interstitial cells of Cajal were noted. These cells are located in the muscularis propria and around the myenteric plexus and serve as pacemakers for the peristaltic contraction of the gastrointestinal tract (*Robinson et al., 2000*).

Interstitial cells of Cajal play important roles, such as the mediator of nitric oxide mediated transmission from nerve terminals to smooth muscle cells in the gastrointestinal tract. Simultaneous expression of specific molecules such as KIT, CD34 and nestin in both ICC's and GISTs leads the pathologists to consider that GISTs may develop from ICCs or their progenitor cells (*Sakurai et al., 2004*).

## 3-Gross Pathology:

Grossly, GISTs are well demarcated spherical masses that appear to arise from the muscularis propria layer of the

gastrointestinal wall. They often project exophytically and/or intraluminally, and they have overlying mucosal ulcerations. Larger GISTs nearly always outgrow their vascular supply, leading to extensive areas of necrosis and haemorrhage (*Pidhorecky et al., 2007*).

Small GISTs often form solid subserosal, intramural, or less commonly polypoid intraluminal masses. A majority of larger GISTs form external, sometimes pedunculated masses attached to outer aspect of gut involving the muscular layers. Many larger tumors are centrally cystic and some develop a diverticulum like appearance with the external tumor communicating by the lumen by a fistulous tract. Some GISTs have an asymmetric hour glass like pattern with a smaller internal and a larger external component (*Miettinen et al., 2005*).

These tumors are usually well circumscribed and generally unencapsulated, though a pseudocapsule maybe present on rare occasions (*Kale et al., 2008*).